Why the study?
There was little evidence regarding the impact of community pharmacist depression screening in adults on clinical and economic outcomes.
Does depression screening by community pharmacists improve clinical and economic outcomes in adults?
Does depression screening by community pharmacists improve clinical and economic outcomes in adults?
Current evidence is insufficient to determine the clinical and economic impact of depression screening by community pharmacists, highlighting the need for larger, well-designed studies.
Answers are grounded in this paper and cite their sources.
Insufficient evidence precludes routine pharmacist-led depression screening; leaves open its clinical and economic value pending larger trials.
Community pharmacists are able to use depression screening tools to identify undiagnosed adults having symptoms of depression. However, there is little evidence around the impact of this screening on clinical and economic outcomes. Larger, well-designed studies that use a highly accurate, easily administered screening tool and include patient referral and follow-up and pharmacist training are warranted to provide evidence on the impact of community pharmacists screening adults for depression.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: